Skip to Content

Bayer AG ADR - Stock Quote BAYRY

Rating as of

Morningstar's Bayer AG ADR Stock Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Buoyed by Strong Crop Science Pricing, Undervalued Bayer Posts Solid Q1 as Drug Pipeline Advances

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA |

Largely buoyed by excellent crop science growth, Bayer reported strong first-quarter results ahead of our expectations, but we don’t expect any major changes to our fair value estimate as we believe the favorable pricing driving the strong performance in the quarter will fade later in the year. Nevertheless, we continue to view the stock as undervalued, with the market underappreciating the firm’s growth potential through patent losses and overly concerned about the glyphosate litigation. Bayer has already taken reserves to cover the downside in the glyphosate legal process, and we don’t see much more negative pressure; if the Solicitor General input to the Supreme Court is favorable, we could see less legal payouts by Bayer.

Read Full Analysis

Bayer AG ADR's Company Profile

Business Description

Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins. The firm has a crop science business that includes seeds, pesticides, herbicides, and fungicides, which was expanded through the acquisition of Monsanto.

Kaiser-Wilhelm-Allee 1
Leverkusen, 51368, Germany
T +49 214301
Sector Healthcare
Industry Drug Manufacturers - General
Most Recent Earnings Mar 31, 2022
Fiscal Year End Dec 31, 2022
Stock Type
Employees 100,753

Bayer AG ADR's Related Articles & News